LATEST NEWS & PUBLICATIONS
CMS Drug Price Negotiation Final Rule: Who Is Affected in 2029?
CMS Drug Price Negotiation Final Rule: Who is Affected in 2029? The Centers for Medicare & Medicaid Services (CMS) has released a final rule addressing the Medicare Drug Price Negotiation Program and related Medicare Part D requirements. The rule primarily affects...
MFN Drug Pricing in 2026: Breaking Down GENEROUS, GLOBE, GUARD & TrumpRx
MFN Drug Pricing in 2026: Breaking Down GENEROUS, GLOBE, GUARD & TrumpRx A straightforward look at five federal drug pricing initiatives, including Medicare and Medicaid rebate changes, manufacturer implications, and 2027 implementation timelines. Regulatory...
DSCSA Implementation Is Driving New State Licensing Requirements for Drug Manufacturers
DSCSA Implementation is Driving New State Licensing Requirements for Drug Manufacturers As implementation of the Drug Supply Chain Security Act (DSCSA) continues, pharmaceutical manufacturers are seeing related changes extend into state manufacturer licensing...
OUR DIFFERENCE
Access
- Direct access to your analyst and company leadership
- Available 24/7 to support your needs
Accuracy
- Apply discipline to fully compliant SOPs
- All deliverables subject to strict layers of reviews and audits
Dependability
- Consistent ownership & business partners
- Vested in your long-term success
Transparency
- Clients own all data
- Full access to all scrubbed data, computations and processes
Problems Solved — Opportunities Leveraged.
Find out how we can support your critical analytic, processing and financial functions.